AUTHORS
Mariano Arribas, Esteban Braggio, PhD2, Kevin Guanwen Shim, MD PhD3, J Erin Wiedmeier-Nutor, MD,MPH4, Linda Baughn, PhD5, Patricia Greipp, DO6, Juana Figueroa Aguirre, MD7, Daniel Bihnam, MS8, P. Leif Bergsagel, MD9, Rafael Fonseca, MD10
AFFILIATIONS
1 Mayo Clinic Arizona, Phoenix, Arizona, United States
2 Mayo Clinic Arizona, Phoenix, Arizona, United States
3 Mayo Clinic Arizona, Phoenix, Arizona, United States
4 Mayo Clinic Arizona, Phoenix, Arizona, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic Arizona, Phoenix, Arizona, United States
8 Mayo Clinic Arizona, Phoenix, Arizona, United States
9 Mayo Clinic Arizona, Phoenix, Arizona, United States
10 Mayo Clinic Arizona, Phoenix, Arizona, United States
ABSTRACT
Chromosomal translocations involving the immunoglobulin heavy chain (IgH) locus are one of the major initiating genetic events in multiple myeloma (MM). Among these, the t(14;16)(q32;q23), involving MAF, and the t(14;20)(q32;q12), involving MAFB, have reported prevalences of 4% and 1%, respectively. Because of their low incidence, most cohorts describing their clinical and demographic features are limited.
A higher proportion of females among patients with t(14;16) has been reported in previous studies, but based on small cohorts, usually with less than 50 patients. Females represented 61-70% in previously published and public datasets (CoMMpass). Data regarding sex distribution in t(14;20) are considerably more limited. In contrast, the more common t(11;14) and t(4;14) appear to be more prevalent in men, as reported in CoMMpass, consistent with the overall male predominance observed in MM.
Here, we present a real-world cohort, the largest series reported to date, for both abnormalities, describing demographic, clinical, and cytogenetic profiles of these translocations at diagnosis. Given the heterogeneity of treatments, prognostic associations were not evaluated.
A dual-source ascertainment strategy was used to identify active or smoldering MM patients harboring MAF family translocations across all Mayo Clinic sites. First, the Mayo Clinic FISH (fluorescence in situ hybridization) database was queried to identify patients with documented t(14;16) or t(14;20). In parallel, the Mayo Data Explorer (MDE) platform was queried to capture Mayo Clinic patients whose FISH testing had been performed externally. Unstructured clinical notes were screened using targeted key words, and predefined LLM-generated prompts were applied to identify documentation of t(14;16) and t(14;20) and to answer related questions. The resulting responses were then reviewed using the Copilot AI assistant, which assigned each patient a confidence score based on consistency across notes, explicit documentation of the translocation, and absence of conflicting information. Cases with a confidence score below 80% underwent manual review. As IgH translocations are primary, patients were classified as t(14;16) or t(14;20) positive based on FISH performed at any point in their clinical course, not exclusively at diagnosis. Gain(1q) analyses were restricted to patients diagnosed on or after July 15, 2014, when routine FISH testing for this marker began.
Baseline demographic, clinical, laboratory, and cytogenetic characteristics were collected, and dates of SMM and active MM diagnosis were manually verified. Continuous variables were compared with the Mann-Whitney U test and categorical variables with the chi-square or Fisher's exact test (P<0.05 considered significant).
A total of 505 unique patients diagnosed with Smoldering MM or MM between November 1988 and October 2025 with a MAF-family IgH translocation were identified. Of these, 367 (72.7%) had t(14;16) and 138 (27.3%) had t(14;20). Both translocations occurred predominantly in women, representing 63.8% and 60.1%, respectively (317/505 overall, 62.8%). This proportion of female patients was significantly greater than the ~45% reported for myeloma populations (p<0.0001 for both translocations).
There were no statistically significant differences between male and female patients when considering isotype, light-chain restriction, plasma cell burden, or the rates of gain(1q), monosomy 13, or del(17p) at diagnosis within either translocation (all p>0.05). However, clinical differences were observed between the two translocation groups. Patients with t(14;20) were more frequently diagnosed at the smoldering stage than those with t(14;16) (16.7% vs. 9.0%, p=0.02). Patients with t(14;16) had a higher plasma cell burden (55% vs. 40%, p<0.001), more frequently had del(17p)/TP53 (13.1% vs. 5.1%, p=0.02), and showed a higher IgA frequency (25.6% vs. 8.0%) with an even Kappa/Lambda distribution, compared with t(14;20), which was predominantly IgG (72.5%) and Kappa-restricted (70.3%) (both p<0.001). Gain(1q) prevalence did not differ significantly between t(14;16) and t(14;20) (61.6% vs. 53.2%, p=0.16-0.20).
In this cohort, the largest reported for t(14;16) and t(14;20), females represented the majority of patients. These findings open the possibility that the early lesions driving them are shaped by sex-related differences in B-cell DNA damage and repair, or in clonal selection. Further mechanistic studies are warranted.
DISCLOSURES
Mariano Arribas: No relevant conflicts of interest to declare.